Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Ovalbumin peptide** refers to specific peptide fragments derived from ovalbumin, a protein found in egg white, frequently used as model antigens in immunology and biomedical research[1][2][3][5][7]. Two of the most widely studied ovalbumin peptides are SIINFEKL (OVA 257-264) and ISQAVHAAHAEINEAGR (OVA 323-339). These peptides are used to study antigen-specific T cell responses: - **SIINFEKL (257-264)** is a MHC class I-restricted (Kb) epitope recognized by CD8+ T cells, commonly used to model cytotoxic T cell responses[1][3][8]. - **ISQAVHAAHAEINEAGR (323-339)** is a MHC class II-restricted epitope recognized by CD4+ T cells, and is used to study T helper cell responses and allergic mechanisms[5]. Ovalbumin peptides can be administered alone or as part of vaccine formulations, with carriers (e.g., alginate nanoparticles) or adjuvants to induce strong immune responses, and have shown immunomodulatory effects, including tumor suppression in preclinical models[2][7]. They are also used experimentally in models of autoimmunity, allergy, and cancer immunotherapy due to their ability to induce robust, antigen-specific immune reactions in genetically defined animal strains[2][3][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ovalbumin peptide.